Alloy Therapeutics raised $40 million in a late-stage Series E to scale its tech-enabled biotech infrastructure, the company said. Alloy plans to use the proceeds to expand discovery and development capabilities across preclinical and clinical development, while building out data and AI layers connecting its platform. Alloy reported a model focused on generating revenue while supporting therapeutic programs created through partnerships. Investors in the round included 8VC, JIC Venture Growth Investments, and Echo Capital, with participation from Mubadala Capital, Presight Capital, and Thiel Capital. The round reflects continued investor appetite for platform and service hybrids that combine operational capacity with data/AI tooling, particularly as biotech companies seek faster iteration across discovery and translation.